JPWO2023032940A5 - - Google Patents

Info

Publication number
JPWO2023032940A5
JPWO2023032940A5 JP2023545576A JP2023545576A JPWO2023032940A5 JP WO2023032940 A5 JPWO2023032940 A5 JP WO2023032940A5 JP 2023545576 A JP2023545576 A JP 2023545576A JP 2023545576 A JP2023545576 A JP 2023545576A JP WO2023032940 A5 JPWO2023032940 A5 JP WO2023032940A5
Authority
JP
Japan
Prior art keywords
disease
pharmaceutically acceptable
acceptable salt
alkyl
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023545576A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023032940A1 (cg-RX-API-DMAC7.html
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2022/032483 external-priority patent/WO2023032940A1/ja
Publication of JPWO2023032940A1 publication Critical patent/JPWO2023032940A1/ja
Publication of JPWO2023032940A5 publication Critical patent/JPWO2023032940A5/ja
Pending legal-status Critical Current

Links

JP2023545576A 2021-09-01 2022-08-30 Pending JPWO2023032940A1 (cg-RX-API-DMAC7.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021142742 2021-09-01
PCT/JP2022/032483 WO2023032940A1 (ja) 2021-09-01 2022-08-30 含窒素三環性化合物及びその医薬用途

Publications (2)

Publication Number Publication Date
JPWO2023032940A1 JPWO2023032940A1 (cg-RX-API-DMAC7.html) 2023-03-09
JPWO2023032940A5 true JPWO2023032940A5 (cg-RX-API-DMAC7.html) 2025-09-02

Family

ID=85411243

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023545576A Pending JPWO2023032940A1 (cg-RX-API-DMAC7.html) 2021-09-01 2022-08-30

Country Status (15)

Country Link
US (1) US20240417406A1 (cg-RX-API-DMAC7.html)
EP (1) EP4438040A4 (cg-RX-API-DMAC7.html)
JP (1) JPWO2023032940A1 (cg-RX-API-DMAC7.html)
KR (1) KR20240055793A (cg-RX-API-DMAC7.html)
CN (1) CN117897382A (cg-RX-API-DMAC7.html)
AR (1) AR126913A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022337617A1 (cg-RX-API-DMAC7.html)
CA (1) CA3228249A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024000633A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024003629A2 (cg-RX-API-DMAC7.html)
IL (1) IL311162A (cg-RX-API-DMAC7.html)
MX (1) MX2024002705A (cg-RX-API-DMAC7.html)
PE (1) PE20240920A1 (cg-RX-API-DMAC7.html)
TW (1) TW202319051A (cg-RX-API-DMAC7.html)
WO (1) WO2023032940A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20211273A1 (es) * 2018-02-01 2021-07-19 Japan Tobacco Inc Compuesto de amida heterociclica nitrogenada y su uso para fines medicos

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ2002773A3 (cs) * 1999-09-04 2002-06-12 Astrazeneca Ab Substituované deriváty N-fenyl-2-hydroxy-2-methyl-3,3,3-trifluorpropanamidu, které zvyąují aktivitu pyruvátdehydrogenázy
AR074797A1 (es) * 2008-10-10 2011-02-16 Japan Tobacco Inc Compuesto de fluoreno , composiciones farmaceuticas , inhibidores de pdhk y pdhk2 , metodos de tratamiento , usos de los mismos y kit comercial
TWI633885B (zh) * 2013-03-15 2018-09-01 日商日本煙草產業股份有限公司 吡唑-醯胺化合物及其醫藥用途
CA2994027C (en) * 2015-07-31 2023-10-10 Merck Patent Gmbh Bicyclic heterocyclic derivatives
PE20211273A1 (es) * 2018-02-01 2021-07-19 Japan Tobacco Inc Compuesto de amida heterociclica nitrogenada y su uso para fines medicos
EP3851103A4 (en) * 2018-09-11 2022-06-08 Japan Tobacco Inc. THERAPEUTIC OR PROPHYLACTIC AGENT FOR CHRONIC KIDNEY DISEASE CONTAINING A PYRAZOLE-AMIDE COMPOUND
MX2021010692A (es) * 2019-03-04 2021-10-01 Japan Tobacco Inc Dispersion solida amorfa de compuesto de pirazol-amida.
BR112022014749A2 (pt) * 2020-03-04 2022-10-11 Japan Tobacco Inc Composto tricíclico fundido e uso medicinal do mesmo

Similar Documents

Publication Publication Date Title
JP2019131544A5 (cg-RX-API-DMAC7.html)
JP2015524443A5 (cg-RX-API-DMAC7.html)
JP2023529354A5 (cg-RX-API-DMAC7.html)
JP2019531320A5 (cg-RX-API-DMAC7.html)
JP2022007994A5 (cg-RX-API-DMAC7.html)
JP2004534825A5 (cg-RX-API-DMAC7.html)
JP2025131625A5 (cg-RX-API-DMAC7.html)
CA2798610A1 (en) Bicyclic heteroaryl compounds as gpr119 modulators
RU2016101964A (ru) СТИМУЛЯТОРЫ sGC
JP2014521700A5 (cg-RX-API-DMAC7.html)
WO2005123680B1 (en) Six-membered heterocycles useful as serine protease inhibitors
RU2005118982A (ru) Производные замещенного дигидропираноиндол-3, 4-диона как ингибиторы ингибитора-1 активатора плазминогена (pai)
JP2011520967A5 (cg-RX-API-DMAC7.html)
MX2022010950A (es) Compuesto triciclico fusionado y uso farmaceutico del mismo.
JP2015533168A5 (cg-RX-API-DMAC7.html)
IL320810A (en) Glucagon-like peptide 1 receptor agonists
JP2020111571A5 (cg-RX-API-DMAC7.html)
RU2007106869A (ru) Тиазол-нафтиловые кислоты как ингибиторы ингибитора активации плазминогена-1
JPWO2021187548A5 (cg-RX-API-DMAC7.html)
RU2007106868A (ru) Оксазол-нафтиловые кислоты и их применение в качестве модуляторов ингибитора активатора плазминогена-1 (pai) для лечения тромбоза и сердечно-сосудистых заболеваний
JP2018522024A5 (cg-RX-API-DMAC7.html)
JP2019507167A5 (cg-RX-API-DMAC7.html)
RU2024108335A (ru) Азотсодержащее трициклическое соединение и его фармацевтическое применение
CL2024000633A1 (es) Compuesto tricíclico que contiene nitrógeno y su uso farmacéutico.
JP2023529196A5 (cg-RX-API-DMAC7.html)